Successful high power testing of CCL modules

RNS Number : 7399F

Advanced Oncotherapy PLC

16 November 2015

 

16 November 2015

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Successful high power testing of CCL modules

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the high power testing of two Coupled Cavity Linac ("CCL") modules at the Company's facility in Geneva has been successfully completed. 

In August the Company announced that the two CCL modules were ready to be tested at high power and marked the first time two CCL modules were tested together. The modules have now been successfully tested at a full power of 7.5MW and full duty cycle at 200Hz. The finished LIGHT system will incorporate 15 CCL modules in total and combined in a series these will accelerate protons to the high energies required to treat radiosensitive tumours.

In addition, tuning has been completed on two further CCL modules at the VDL ETG Projects ("VDL") headquarters and these are ready to be delivered to the Geneva facility at the end of this month. VDL has in-depth experience and a solid track record in building accelerating modules and is Advanced Oncotherapy's key supply partner for the CCL modules. 

The CCL modules or "higher speed accelerators" are an essential part of the LIGHT system. They consist of a series of cells which accelerate the protons from energies of 37.5 Mega-electron Volts (MeV) to energies that can be applied usefully to a clinical setting.

Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said: "The successful conclusion of the CCL tests gives us confidence that the modules will work under the required conditions to deliver the high energy protons that we need to treat patients effectively. We have tested them on maximum power with no complications, and this is another important milestone in delivering our first LIGHT machine."

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Beaufort Securities (Joint Broker)
Jon Levinson / Elliot Hance	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

MSCLLFVRLVLVLIE